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Abstract: (176 words; max 200) 
Despite promising findings from small-scale studies suggesting that body psychotherapy may be an 
effective treatment for negative symptoms, these results were not replicated in a recent multisite trial. 
In this trial a far smaller proportion of women were recruited relative to earlier studies, which may be an 
issue given the gender mix of the sample evaluated has been found to affect trial outcomes in 
schizophrenia. Using data from our multisite trial, the interaction between gender and treatment 
allocation as a predictor of outcomes was examined in 275 participants (72 women and 203 men) 
randomised to either a body psychotherapy or Pilates group. Negative symptoms were found to 
significantly reduce in women randomised to the body psychotherapy condition in comparison to 
Pilates, while no such effect was detected in men. Consistent with the smaller trials, this improvement 
was found to relate predominantly to expressive deficits. These findings suggest that body 
psychotherapy may be an effective treatment for negative symptoms in women. These findings 
emphasise the importance of sample characteristics in determining trial outcome in psychological 
treatment studies.  
 
Highlights: 
 Body psychotherapy may be an effective treatment for negative symptoms in women 
 The effect of body psychotherapy in women is specific to expressive deficits 
 Highlights importance of sample characteristics in clinical trials of psychotherapy 
 1. Introduction 
Negative symptoms of schizophrenia are strongly associated to social and functional impairment 
(Hunter and Barry, 2012; Lysaker and Davis, 2004; Milev et al., 2005), and are unresponsive to current 
treatments (Fusar-Poli et al., 2015). As a result, these symptoms are considered an important unmet 
therapeutic need in a large proportion of cases (Kirkpatrick et al., 2006). Negative symptoms comprise of 
two distinct subdomains, with anhedonia, amotivation and asociality representing experiential deficits, 
and alogia and blunted affect representing expressive deficits (Blanchard and Cohen, 2006; Horan et al., 
2011). In the 2014 NICE guidelines (NICE, 2014), creative arts therapies, such as body psychotherapy, 
were recommended as an effective treatment for negative symptoms. However, in a recent large-scale 
trial of body psychotherapy, no effects of treatment of negative symptoms were detected (Priebe et al., 
2016).  
The body psychotherapy NESS trial (Priebe et al., 2016) was an advance on smaller studies by being 
adequately powered to detect clinically meaningful differences, including 275 participants. The trial had 
good internal and external validity with a high rating on the Clinical Trials Assessment Measure (88/100), 
designed to provide quality ratings for psychological treatment studies (Tarrier and Wykes, 2004). 
Therapy was fully manualised with consistently high treatment fidelity, and the treatment was 
compared to an active control condition to account for the non-specific effects of structured group 
activity. Group attendance rates in both arms compared favourably with similar creative arts therapies 
studies with this patient population (Crawford et al., 2012), while the study retention rate was excellent 
(96.7% at end of treatment).  
Two other randomised controlled trials have been identified as providing data on the effects of body 
psychotherapy in addition to the NESS trial (Martin et al., 2016; Röhricht and Priebe, 2006). In the 
Röhricht and Priebe (2006) study large effect size improvements in negative symptoms were detected as 
compared to a supporting counselling group, with significant improvements in blunted affect and motor 
retardation evident. In the Martin et al. (2016) study, similar effect size improvements were detected 
relative to treatment-as-usual, with strong improvements found in blunted affect in particular. In NESS, 
while no effect on negative symptoms was detected, a significant treatment effect on expressive deficits 
was found, suggesting a greater degree of consistency between the study findings than a first evaluation 
of the primary outcomes may suggest. Given the current lack of clinically effective treatments for 
negative symptoms (Fusar-Poli et al., 2015), exploring why this large scale trial did not replicate the 
findings of the smaller studies may be important in improving recovery opportunities for at least some 
people with psychosis. 
The reason for the differences in outcomes between these studies and the NESS trial is currently 
unclear. Given physical activity has been found to improve various aspects of psychological wellbeing in 
schizophrenia (Holley et al., 2011), it is possible that both arms of the NESS study were equally effective. 
However, the small within-group improvements suggest that this alone cannot account for the 
differences noted between the studies. A second possibility may relate to variations in the recruited 
samples. Many of the socio-demographic and clinical characteristics reported in the three studies were 
similar. One notable exception to this however is that in the full-scale trial a far lower proportion of 
women were recruited; in the NESS study, 24% of the sample were women, in comparison to 51% in the 
Röhricht study and 47% in the Martin study. This may be significant, given men have been found to 
experience significantly poorer premorbid and social functioning (Goldstein and Link, 1988), more 
pervasive neurodevelopmental abnormalities (Nopoulos et al., 1997), earlier illness onset (Häfner, 
2003), are typically less emotionally expressive in response to external stimuli (Kring & Gordon, 1998), 
and to be more likely to experience extra-pyramidal side effects (Smith, 2010), all of which may impact 
treatment response in negative symptoms. However, while there is some evidence to suggest that 
women respond better to antipsychotic treatment (Abel et al., 2010; Usall et al., 2007), and CBT-
orientated treatment for depressed patients with chronic pain (Pieh et al., 2012), we could find no 
studies examining the impact of gender on treatment response in group psychosocial interventions for 
schizophrenia. While there is some evidence to suggest that negative symptoms are both more severe 
and more prevalent in males (Galderisi et al., 2012; Morgan et al., 2008), a number of other studies have 
found no differences between the sexes (see Ochoa et al., 2012), suggesting that negative symptoms 
remain a significant issue for both men and women. 
The primary aim of this study was to assess the moderating effects of gender on body psychotherapy as 
a treatment for negative symptoms using the NESS data (Priebe et al., 2016). Given the effects of body 
psychotherapy in the earlier studies have been found predominantly in expressive symptoms such as 
blunted affect (Martin et al., 2016; Röhricht and Priebe, 2006), analysis on expressive and experiential 
deficits were considered separately, in addition to assessing negative symptoms as a single construct. In 
the Röhricht study, clinical improvements were found to occur in negative symptoms only (Röhricht and 
Priebe, 2006), so an examination of the interaction effect between gender and treatment allocation on 
positive and general symptoms was completed to examine the specificity of the effect, and the 




The study is a secondary analysis of a blinded, parallel-arm randomised controlled trial. A full description 
of the design is outlined in the protocol (Priebe et al., 2013), and details of the procedures and study 
implementation are available in the published full report (Priebe et al., 2016). All participants were 
randomised, with equal probability, to a 20-session body psychotherapy or Pilates group. 
 
2.2. Participants 
All participants were outpatients recruited from five different NHS Trusts across the UK. The inclusion 
criteria included an ICD-10 diagnosis of schizophrenia; a score of ≥18 on the Positive and Negative 
Syndrome Scale (PANSS) negative subscale (Kay et al., 1987); no change in the type of antipsychotic 
medication prescribed for at least 6 weeks; aged 18-65; an ability to provide informed consent; and a 
willingness and ability to participate in physically active groups. Prior to recruitment all participants 
provided informed consent.  
 
2.3. Outcomes 
In accordance with the original trial, the main outcome of interest for this investigation was the PANSS 
negative subscale at end of treatment (Kay et al., 1987). Expressive and experiential symptoms were 
examined separately using the Clinical Assessment Interview for Negative Symptoms (CAINS; Kring et al., 
2013). The CAINS is a 13-item semi-structured interview designed to address the methodological and 
conceptual limitations of earlier negative symptom assessment tools (Blanchard et al., 2011). The 
experiential subscale consists of nine items, measuring how frequently they take part in social and 
occupational activities, their anticipation of pleasure, and their motivation to complete activities and 
develop or maintain relationships. The expressive subscale consists of four items, measuring deficits in 
vocal and gestural aspects of expression. 
In order to examine the specificity of the findings, the PANSS positive and general subscales were 
evaluated. The Calgary scale was adopted as a measure of depression (Addington et al., 1993), EPS were 
measured using the Simpson Angus Scale (SAS; Simpson and Angus, 1970), and the number of social 
contacts participants reported over the previous week was recorded using an adapted version of the 
Social Network Scale (SNS; Dunn et al., 1990). The Client Service Questionnaire was included as a 
measure of treatment acceptability at end of treatment (CSQ; Attkisson and Zwick, 1982). Finally, the 
number of sessions each participant attended were assessed, recorded by the group co-facilitators after 
every session. 
 
2.4. Body psychotherapy condition 
The body psychotherapy treatment was a 90-minute, 20-session group intervention held twice a week 
on non-consecutive days. The group was facilitated by an accredited dance movement psychotherapist, 
and assisted by a volunteer co-facilitator. The structure of the therapy is outlined in the published 
manual (Röhricht, 2000) and comprises of five sections. The first section is an opening circle to initiate 
communication between participants and draw focus towards the body. The second is a warm-up 
section to stimulate, promote self-awareness, and conduct reality testing exercises. The third includes 
structured exercises to address bodily disturbances. The fourth includes creative exercises to encourage 
the use of body as a source of expression and enjoyment. The fifth section is a closing circle, used to 
review session and disengage from the therapeutic process. In all sections, a key component of the 
therapy is the facilitation and development of verbal and pre-verbal communication between 
participants. 
 
2.5. Physical activity group condition (Pilates) 
In order to mirror the structure of the body psychotherapy intervention, the physical activities group 
was also a 90-minute, 20-session group held twice a week on non-consecutive days, held in the same 
venue as each corresponding body psychotherapy group. The groups were facilitated by an accredited 
Pilates instructor, and assisted by a volunteer co-facilitator. The group was structured as a beginners-
level Pilates group, with a guide developed based upon the Pilates Union Matwork Manual (Newham, 
2010).  
 2.5. Analysis plan 
In the first part of the analysis, the impact of gender on treatment effectiveness for negative symptoms 
as a single construct was examined. A mixed-effects model, fitted by restricted maximum likelihood, was 
used with the PANSS negative symptom subscale at end of treatment included as the dependent 
variable, with fixed effects for the baseline PANSS negative subscale score, gender, treatment allocation, 
and the study centre (which was used in the randomisation stratification). A random effect for the 
therapy group was included to model for any clustering by group. To examine the impact of gender on 
treatment outcome, an interaction term between gender and treatment allocation was included, and 
assessed for significance using the Wald statistic.  
As part of the analysis, a number of potential extraneous factors which may explain any effect of gender 
on treatment outcomes were considered. These include: baseline depression scores, given depression 
can induce secondary negative symptoms (Carpenter et al., 1985), can respond to body psychotherapy 
(Röhricht et al., 2013), and is typically more severe in women with psychosis (Goldstein and Link 1988). 
Extrapyramidal symptoms (EPS), given these can mimic negative symptoms (Carpenter et al., 1985) and 
are more prevalent in men on antipsychotic medication (Abel et al., 2010). Number of social contacts, 
due to women with psychosis typically having a more developed social network (Thorup et al., 2006), 
which may allow for more opportunities to implement any skills learnt during treatment. Prescribed 
antipsychotic medication dose was also included, with the equivalence between different medications 
calculated using the defined daily dose (DDD; WHO, 2012). These variables were included as covariates 
in the model, along with group attendance rates and treatment satisfaction reported at end of 
treatment to control for the possibility of any effect of treatment being attributable to differences in 
treatment acceptability, or a dose-response effect. Due to the very high retention rate of the original 
trial between baseline and follow-up (96.7%), multiple imputation was not used, and the analysis was 
based on an available case basis following intention to treat principles.  
In the second part of the analysis, expressive and experiential deficits as measured by the CAINS were 
evaluated in order to determine whether any effect of treatment was specific to one particular domain 
of negative symptoms. In addition, the PANSS positive and general symptom subscales were evaluated 
in order to determine the specificity of the findings, using the same model previously outlined. 
 
3. Results 
3.1. Baseline characteristics 
The baseline characteristics of the sample, stratified by gender, are presented in Table 1. Of the 275 
participants recruited, 203 were men (103 randomised to body psychotherapy and 100 to Pilates) and 
72 were women (37 randomised to body psychotherapy and 35 to Pilates).  
[Insert Table 1 here] 
3.2. Impact of gender on treatment outcomes of body psychotherapy on negative symptoms  
The mean symptom levels at baseline and end of treatment, stratified by gender, are presented in Table 
2. The interaction effect between gender and treatment allocation was found to be significant (Wald’s 
statistic= 4.61, p=0.032; adjusted difference in means: -2.18; 95% CI= -4.17 to -0.19), with women 
experiencing a greater reduction in negative symptoms when randomised to body psychotherapy, 
relative to men. Men randomised to the Pilates condition reported a slightly larger reduction in negative 
symptoms relative to those randomised to body psychotherapy (PANSS negative symptom mean 
change= -1.01 and -1.95 points respectively). In contrast, women randomised to the Pilates group 
reported only a very small reduction in negative symptoms (mean change=-0.27 points), in comparison 
to a moderate reduction in those randomised to body psychotherapy (mean change=-2.55 points). In 
the adjusted model, after controlling for baseline depressive symptoms, EPS, number of social contacts, 
attendance rates, DDD, and treatment satisfaction, the interaction remained significant (Wald’s 
statistic= 7.22, p=0.007; adjusted difference in means= -3.21, 95% CI -5.55 to -0.87). 
[Insert Table 2 here] 
 
3.3. Impact of gender on treatment outcomes for experiential and expressive deficits. 
To determine whether the effect of body psychotherapy on negative symptoms in women relate to 
expressive or experiential deficits (or both), the analysis completed using the PANSS negative subscale 
was replicated using the CAINS subscales. With the CAINS experiential subscale, no interaction effect 
between gender and treatment allocation was detected on outcome (Wald’s statistic= 0.06, p=0.799). In 
the CAINS expressive subscale however a significant interaction effect on outcome between gender and 
treatment allocation was detected (Wald’s statistic= 4.03, p=0.045; adjusted difference in means= -0.34, 
95% CI -0.68 to -0.01.). In men, a small reduction in expressive symptoms was detected in participants 
allocated both to the body psychotherapy and the Pilates group (mean change= -0.10 and -0.12 
respectively). In women however, a small decrease in symptoms was detected in women who were 
randomised to the body psychotherapy group (mean change=-0.30), while a small increase was detected 
in those allocated to the Pilates group (mean change=0.31).  
In the adjusted model controlling for baseline depressive symptoms, EPS, DDD, number of social 
contacts, attendance rates and treatment satisfaction, the interaction as a predictor of expressive 
deficits remained significant (Wald’s statistic=6.59, p=0.010; adjusted difference in means= -0.50, 95% CI 
-0.88 to -0.12), while not significant for experiential deficits (Wald’s statistic= 0.32, p=0.573).  
 
3.4. Impact of gender on treatment outcomes for positive and general psychotic symptoms 
To examine the specificity of the findings, interaction effects between gender and treatment allocation 
in other areas of psychopathology were examined using the PANSS positive and general symptom 
subscales. No significant interaction effect was detected between gender and treatment allocation in 
positive symptoms (Wald’s statistic=0.16, p=0.690) or general symptoms (Wald’s statistic=1.45, 
p=0.229).  
 4. Discussion 
4.1. Main findings 
Body psychotherapy was found to significantly reduce negative symptoms of schizophrenia relative to 
Pilates, however this effect was found only with women. Similar to earlier studies, the improvements 
were found only to occur in expressive, rather than experiential deficits, whilst no effect of treatment 
was detected in positive or general psychotic symptoms. These results were consistent after controlling 
for a number of possible extraneous variables, such as baseline depressive symptoms, EPS, and social 
network size, and not appear to be attributable to treatment acceptability or a dose-response effect.  
 
4.2. Strengths and weaknesses   
The study has a number of strengths. The analysis was completed on data from a rigorously conducted, 
blinded-trial with high inter-rater reliability between the assessors, good therapist fidelity to treatment, 
reasonable therapy group attendance rates, and excellent study retention rates. In addition, the original 
NESS study is by far the largest clinical trial to be conducted in the field of body psychotherapy to date. 
As a result, it is likely that this is the only dataset in which interaction effects could be appropriately 
examined. The results were consistent with earlier findings, and did not appear to be related to a 
number of potential extraneous factors such as depressive symptoms, EPS, the individuals social 
network size, treatment satisfaction, or a dose response effect.  
One important caveat to these findings is the fact that this analysis should be considered only 
exploratory in nature. As a result, including a pre-planned sub-group analysis examining the impact of 
gender on treatment outcomes in any future trials on body psychotherapy for negative symptoms would 
be highly informative. In addition, it is important to note that in the exploratory trial (Röhricht and 
Priebe, 2006) the mean reduction of negative symptoms found in the body psychotherapy arm, relative 
to the supportive counselling group, was larger than the difference between sexes found in the current 
investigation. As a result, the impact of sample difference alone cannot account for the differences 
between the study results. Whilst far from certain, it is possible that a number of other factors may have 
contributed. These include the non-specific effects of physical activity from the Pilates group, greater 
difficulties in maintaining blinding in the clinical setting that the exploratory trial was conducted in, and 
a possible therapist “practice effect” (Gold et al., 2012), which may have reduced the therapist 
effectiveness in NESS given each therapist could only run a maximum of two groups. 
Another important issue to consider is that it is currently unclear why the NESS study recruited a 
significantly smaller proportion of women in comparison to the earlier studies. Whilst men have a 
slightly higher incidence rate of psychosis (1.4:1 men to women, 58%), the prevalence of the disorder 
between the sexes has been found to be broadly similar (McGrath et al., 2008). As a result, the finding 
that the NESS study included almost three times more men than women was surprising, even after 
accounting for the fact that men typically experience more severe negative symptoms and so a higher 
proportion may have been eligible (Ring et al., 1997). The demographic details of those who refused to 
participate in this study were not recorded, so it is unclear whether women were more likely to reject 
participation, or if they were less likely to be identified as potentially eligible. However, in both cases 
this may have introduced a selection bias whereby only the most appropriate women were included in 
the study, whilst a broader range of men were included. This being the case, these findings highlight the 
importance of considering sample-level characteristics both at the point of analysis, and at recruitment 
in future clinical trials for mental health disorders.  
Another important point to consider is that while the treatment was found to be significantly more 
effective in women, it is unclear whether a reduction of only 2.55 points on the PANSS negative subscale 
translates into a clinically meaningful benefit. Given the significant impact of these symptoms on 
functioning and the current paucity of effective treatments (Hunter and Barry, 2012; Fusar-Poli et al., 
2015), it is arguable even small improvements may be viewed as important. However, it is noteworthy 
that this reduction is below the 3-points change used in the original trial as an indicator of a clinically 
significant treatment effect (Priebe et al., 2013). Lastly, it is important to note that women randomised 
to the body psychotherapy group reported higher negative symptoms at baseline, relative to those 
randomised to Pilates. As a result, it is possible that the effect may be at least in part attributable to a 
regression to the mean. That said, in a pre-planned  
 
4.3. Comparisons to the broader literature and future work 
The finding that body psychotherapy appears to be an effective treatment for negative symptoms in 
female participants, but not male participants, may in-part reconcile the differences in outcomes noted 
in the NESS trial and other recent, small-scale studies (Martin et al., 2016; Priebe et al., 2016; Röhricht 
and Priebe, 2006). In the Röhricht study 51% of participants were female, and significant improvements 
in negative symptoms and blunted affect in particular were detected in the body psychotherapy arm, as 
compared to supportive counselling. A similar proportion of men to women were recruited in a recent 
study completed by Martin and colleagues (47% women), and similar improvements in negative 
symptoms and blunted affect in favor of body psychotherapy over treatment-as-usual were again 
detected. The current investigation suggests that the high proportion of men recruited into the NESS 
study may have masked a treatment effect on negative symptoms which is predominantly specific to 
women. Consistent with the smaller studies, the improvement in women noted was found to be related 
specifically to expressive deficits. 
Given the relatively small treatment effect and post-hoc nature of this investigation a replication of 
these findings in a pre-planned analysis is required. If a consistent difference in treatment response is 
detected between men and women, then further work understanding the possible mechanism 
explaining such an effect would be informative. One possible explanation could be that there is 
consistent evidence to suggest that men have an earlier onset of schizophrenia relative to women 
(Angermeyer and Kühnz, 1988; Häfner 2003), with women, on average, being 3-5 years older at first 
admission. In addition, women with schizophrenia have typically been found to have better social and 
occupational functioning (Salokangas and Stengård 1990; Shtasel et al., 1992; Usall et al., 2002), which 
may be attributable to the fact that a later onset allows women to achieve more stability in their 
occupational and social roles before becoming ill (Riecher‐Rössler and Häfner, 2000; Riecher-Rössler and 
Rössler, 1998). As noted by Riecher‐Rössler, these differences may result in different treatment goals 
between the sexes, resulting in different treatment approaches being necessary in order to achieve 
these aims. This hypothesis is supported by the socio-demographic characteristics of this sample, where 
women were found more likely to have children and less likely to live alone, suggesting a more 
developed social network and role.  
   
4.4. Final conclusions 
The findings suggest that body psychotherapy may be an effective treatment for negative symptoms of 
schizophrenia in women, but not men. The reasons for this difference are not fully understood and 
replication is required before firmer conclusions can be drawn. However, the differences in outcome 
may be related to functioning being more impaired in male participants, resulting in the goals of therapy 
being different between the sexes (Riecher‐Rössler and Häfner, 2000). These findings support the idea 
that not all psychotherapies may be equally appropriate for everyone with a particular symptom 
presentation. This study also emphasises the importance of exploring sample-level characteristics in 
trials of psychosocial treatments, and may in part account for why results from small-scale studies are 
sometimes not replicated in larger clinical trials.  
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Table 1: Sample characteristics, by gender     
  Men Women 
    n=203 n=72 
    
Centre: n (%)   
 East & North East London 68 (33.5) 29 (40.3) 
 South London 50 (24.6) 14 (19.4) 
 Manchester 34 (16.8) 12 (16.7) 
 Liverpool 51 (25.1) 17 (23.6) 
    
Age: mean (SD) 42.07 (10.72) 42.51 (10.40) 
    
Duration of illness: median (IQR) 10 (7 – 17) 12 (7 – 20) 
    
Number of hospitalisations: median (IQR) 3 (1 - 5) 3.5 (1.5 - 7) 
    
Live alone: n (%) 146 (71.9%) 34 (47.2%) 
    
Have at least one child: n (%) 53 (26.4%) 36 (50.7%) 
    
PANSS total score: mean (SD)   
 Negative subscale 23.34 (4.50) 22.62 (3.81) 
 Positive subscale 13.89 (4.90) 14.54 (5.02) 
 General subscale 33.41 (8.45) 35.56 (8.08)     
CAINS total score: mean (SD)   
 CAINS Expressive subscale 2.42 (0.63) 2.43 (0.58) 
 CAINS Experiential subscale 2.00 (0.89) 1.79 (1.02) 
        
Calgary Depression Scale: mean (SD) 4.47 (4.15) 5.32 (4.89) 
    
Antipsychotic Dose (DDD): mean (SD) 1.65 (1.28) 1.45 (0.97) 
    
SD, standard deviation; IQR, Inter-quartile range; PANSS, Positive and Negative Syndrome 




 Table 2: Comparison of symptom outcomes in the body psychotherapy and Pilates at end of treatment, after controlling for covariates, by gendera 
Variables 
Men (n=203)   Women (n=72)  
Adjusted difference in 
means, by gender 
(95% CI's)b 
Body Psychotherapy (n=103)   Pilates (n=100)  Body Psychotherapy (n=37)  Pilates (n=35)  
Baseline 
End of 
treatment   Baseline 
End of 
treatment   Baseline 
End of 
Treatment   Baseline 
End of 
Treatment   
  
             
PANSS              
 Negative  22.93 (4.37) 21.92 (5.29)  23.77 (4.62) 21.82 (4.69)  24.14 (4.07) 21.59 (5.67)  20.97 (2.71) 20.70 (4.54)  -2.18 (-4.17 to -0.19) 
 Positive 13.87 (5.24) 13.32 (4.97)  13.91 (4.55) 13.30 (4.29)  14.50 (4.80) 12.64 (3.88)  14.57 (5.30) 13.24 (4.20)  -0.36 (-2.15 to 1.42) 
 General 33.30 (8.60) 31.25 (8.01)  33.53 (8.34) 30.86 (7.44)  36.75 (7.81) 32.08 (9.11)  34.34 (8.29) 31.82 (7.44)  -1.77 (-4.66 to 1.12) 
               
CAINS              
 Expressive 1.95 (0.83) 1.85 (0.88)  2.04 (0.95) 1.92 (1.02)  2.13 (1.01) 1.79 (1.07)  1.41 (0.90) 1.72 (1.07)  -0.34 (-0.68 to -0.01) 
 Experiential 2.42 (0.63) 2.29 (0.65)  2.42 (0.63) 2.26 (0.63)  2.56 (0.60) 2.26 (0.62)  2.29 (0.54) 2.03 (0.66)  0.03 (-0.23 to 0.30) 
                              
Key: PANSS, Positive and Negative Syndrome Scale; CAINS, Clinical Assessment Interview for Negative Symptoms. Values represent mean scores, with standard deviations denoted in 
brackets (unless otherwise stated). 
a Covariates in the model include fixed effects for baseline symptom scores and study centre, and random effects for treatment group. 
b Negative value indicates greater symptomatic improvement in women in the body psychotherapy group. 
